Keeping You Informed

The number of people surviving cancer has improved hugely in the past 50 years, but experts warn progress has been uneven with some cancers with the worst survival rates falling further behind.

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.

Given the rising incidence of colorectal cancer — particularly among younger adults — and ongoing threats to preventive screening in the U.S., the need for timely, optimized CRC screening is greater than ever.

The 340B Drug Pricing Program was created to improve access to care for low-income and uninsured patients at safety-net hospitals and clinics.

Upcoming Advocacy Chat: Your Source for Policy & Cancer Research .....

New COA & CancerCare Screening Campaign, Time to Screen. During .....

Paving the Path for a World Without Colon Cancer. Colorectal .....